Telix Pharmaceuticals (NASDAQ:TLX) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Telix Pharmaceuticals (NASDAQ:TLX) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Several other analysts have also issued reports on the company. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Tuesday, January 27th. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Telix Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Price Performance

Shares of NASDAQ:TLX opened at $7.08 on Friday. Telix Pharmaceuticals has a 1 year low of $6.87 and a 1 year high of $30.36. The business’s 50 day simple moving average is $8.02 and its 200 day simple moving average is $9.64.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in TLX. Rhumbline Advisers boosted its position in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares in the last quarter. IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $213,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at $217,000. JPMorgan Chase & Co. bought a new stake in Telix Pharmaceuticals during the 3rd quarter worth $243,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Telix Pharmaceuticals in the 2nd quarter worth about $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.